Old name, new purpose: why we’ve gone back to RNID

Hearing Medicines Discovery Syndicate

The Hearing Medicines Discovery Syndicate has been enabled by a strategic partnership between RNID and the Medicines Discovery Catapult.

The Syndicate will accelerate the development of therapeutics to prevent and treat hearing loss and tinnitus by offering a broad range of support to innovators within academia and commercial organisations.

The Syndicate brings together the following organisations with unique knowledge, expertise and specialised networks in hearing research, drug discovery and development: the National Institute for Health Research (NIHR) through its Biomedical Research Centres (BRC) with leading academic expertise in hearing research from University College London Hospitals BRC, Nottingham BRC and Manchester BRC, and the Cell and Gene Therapy Catapult.

Through the Syndicate, innovators will be able to:

  • Forge links with experts in hearing research, to access know-how and expertise in clinical trial design and cell and gene therapies, as well as specialist CROs and CMOs
  • Access collaboration opportunities with the Syndicate partners and other organisations within our extended network of industry and academic contacts, clinical trial delivery infrastructure, market intelligence and patient insight.

Find out more about the Syndicate.

We recently announced a global call for applications to take part in the first Boehringer Ingelheim Office Hours dedicated to Hearing Loss, a mentoring initiative for innovators from academia and early/pre-seeds biotechs working on the discovery of treatments for hearing loss and tinnitus.